Cargando…
A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life
BACKGROUND: Physiologically-based pharmacokinetic (PBPK) modeling has received growing interest as a useful tool for the assessment of drug pharmacokinetics by continuous knowledge integration. OBJECTIVE: The objective of this study was to build a ciprofloxacin PBPK model for intravenous and oral do...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267540/ https://www.ncbi.nlm.nih.gov/pubmed/29737457 http://dx.doi.org/10.1007/s40262-018-0661-6 |
_version_ | 1783376098222931968 |
---|---|
author | Schlender, Jan-Frederik Teutonico, Donato Coboeken, Katrin Schnizler, Katrin Eissing, Thomas Willmann, Stefan Jaehde, Ulrich Stass, Heino |
author_facet | Schlender, Jan-Frederik Teutonico, Donato Coboeken, Katrin Schnizler, Katrin Eissing, Thomas Willmann, Stefan Jaehde, Ulrich Stass, Heino |
author_sort | Schlender, Jan-Frederik |
collection | PubMed |
description | BACKGROUND: Physiologically-based pharmacokinetic (PBPK) modeling has received growing interest as a useful tool for the assessment of drug pharmacokinetics by continuous knowledge integration. OBJECTIVE: The objective of this study was to build a ciprofloxacin PBPK model for intravenous and oral dosing based on a comprehensive literature review, and evaluate the predictive performance towards pediatric and geriatric patients. METHODS: The aim of this report was to establish confidence in simulations of the ciprofloxacin PBPK model along the development process to facilitate reliable predictions outside of the tested adult age range towards the extremes of ages. Therefore, mean data of 69 published clinical trials were identified and integrated into the model building, simulation and verification process. The predictive performance on both ends of the age scale was assessed using individual data of 258 subjects observed in own clinical trials. RESULTS: Ciprofloxacin model verification demonstrated no concentration-related bias and accurate simulations for the adult age range, with only 4.8% of the mean observed data points for intravenous administration and 12.1% for oral administration being outside the simulated twofold range. Predictions towards the extremes of ages for the area under the plasma concentration–time curve (AUC) and the maximum plasma concentration (C(max)) over the entire span of life revealed a reliable estimation, with only two pediatric AUC observations outside the 90% prediction interval. CONCLUSION: Overall, this ciprofloxacin PBPK modeling approach demonstrated the predictive power of a thoroughly informed middle-out approach towards age groups of interest to potentially support the decision-making process. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40262-018-0661-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6267540 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-62675402018-12-11 A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life Schlender, Jan-Frederik Teutonico, Donato Coboeken, Katrin Schnizler, Katrin Eissing, Thomas Willmann, Stefan Jaehde, Ulrich Stass, Heino Clin Pharmacokinet Original Research Article BACKGROUND: Physiologically-based pharmacokinetic (PBPK) modeling has received growing interest as a useful tool for the assessment of drug pharmacokinetics by continuous knowledge integration. OBJECTIVE: The objective of this study was to build a ciprofloxacin PBPK model for intravenous and oral dosing based on a comprehensive literature review, and evaluate the predictive performance towards pediatric and geriatric patients. METHODS: The aim of this report was to establish confidence in simulations of the ciprofloxacin PBPK model along the development process to facilitate reliable predictions outside of the tested adult age range towards the extremes of ages. Therefore, mean data of 69 published clinical trials were identified and integrated into the model building, simulation and verification process. The predictive performance on both ends of the age scale was assessed using individual data of 258 subjects observed in own clinical trials. RESULTS: Ciprofloxacin model verification demonstrated no concentration-related bias and accurate simulations for the adult age range, with only 4.8% of the mean observed data points for intravenous administration and 12.1% for oral administration being outside the simulated twofold range. Predictions towards the extremes of ages for the area under the plasma concentration–time curve (AUC) and the maximum plasma concentration (C(max)) over the entire span of life revealed a reliable estimation, with only two pediatric AUC observations outside the 90% prediction interval. CONCLUSION: Overall, this ciprofloxacin PBPK modeling approach demonstrated the predictive power of a thoroughly informed middle-out approach towards age groups of interest to potentially support the decision-making process. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40262-018-0661-6) contains supplementary material, which is available to authorized users. Springer International Publishing 2018-05-08 2018 /pmc/articles/PMC6267540/ /pubmed/29737457 http://dx.doi.org/10.1007/s40262-018-0661-6 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Article Schlender, Jan-Frederik Teutonico, Donato Coboeken, Katrin Schnizler, Katrin Eissing, Thomas Willmann, Stefan Jaehde, Ulrich Stass, Heino A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life |
title | A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life |
title_full | A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life |
title_fullStr | A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life |
title_full_unstemmed | A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life |
title_short | A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life |
title_sort | physiologically-based pharmacokinetic model to describe ciprofloxacin pharmacokinetics over the entire span of life |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267540/ https://www.ncbi.nlm.nih.gov/pubmed/29737457 http://dx.doi.org/10.1007/s40262-018-0661-6 |
work_keys_str_mv | AT schlenderjanfrederik aphysiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife AT teutonicodonato aphysiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife AT coboekenkatrin aphysiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife AT schnizlerkatrin aphysiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife AT eissingthomas aphysiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife AT willmannstefan aphysiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife AT jaehdeulrich aphysiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife AT stassheino aphysiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife AT schlenderjanfrederik physiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife AT teutonicodonato physiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife AT coboekenkatrin physiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife AT schnizlerkatrin physiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife AT eissingthomas physiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife AT willmannstefan physiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife AT jaehdeulrich physiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife AT stassheino physiologicallybasedpharmacokineticmodeltodescribeciprofloxacinpharmacokineticsovertheentirespanoflife |